Elanco Animal Health Incorporated (NYSE:ELAN) went down by -3.00% from its latest closing price compared to the recent 1-year high of $34.09. The company’s stock price has collected -0.32% of loss in the last five trading sessions. Press Release reported on 01/11/21 that Elanco Begins Next Phase of Integration Post-Bayer Animal Health Acquisition; Executive Committee Member Sarena Lin to Depart
Is It Worth Investing in Elanco Animal Health Incorporated (NYSE :ELAN) Right Now?
Opinions of the stock are interesting as 8 analysts out of 15 who provided ratings for Elanco Animal Health Incorporated declared the stock was a “buy,” while 0 rated the stock as “overweight,” 6 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $33.67, which is $0.89 above the current price. ELAN currently public float of 452.23M and currently shorts hold a 3.39% ratio of that float. Today, the average trading volume of ELAN was 4.54M shares.
ELAN’s Market Performance
ELAN stocks went down by -0.32% for the week, with a monthly jump of 9.28% and a quarterly performance of -4.60%, while its annual performance rate touched 6.93%. The volatility ratio for the week stands at 2.87% while the volatility levels for the past 30 days are set at 3.06% for Elanco Animal Health Incorporated. The simple moving average for the period of the last 20 days is 2.44% for ELAN stocks with a simple moving average of 19.73% for the last 200 days.
Analysts’ Opinion of ELAN
Barclays, on the other hand, stated in their research note that they expect to see ELAN reach a price target of $25, previously predicting the price at $35. The rating they have provided for ELAN stocks is “Underweight” according to the report published on November 09th, 2020.
Morgan Stanley gave a rating of “Overweight” to ELAN, setting the target price at $31 in the report published on August 20th of the previous year.
ELAN Trading at 2.93% from the 50-Day Moving Average
After a stumble in the market that brought ELAN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.15% of loss for the given period.
Volatility was left at 3.06%, however, over the last 30 days, the volatility rate increased by 2.87%, as shares surge +9.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.97% upper at present.
During the last 5 trading sessions, ELAN fell by -0.32%, which changed the moving average for the period of 200-days by +38.60% in comparison to the 20-day moving average, which settled at $30.70. In addition, Elanco Animal Health Incorporated saw 2.09% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ELAN starting from BAYER AKTIENGESELLSCHAFT, who sale 54,500,000 shares at the price of $29.84 back on Dec 03. After this action, BAYER AKTIENGESELLSCHAFT now owns 18,446,429 shares of Elanco Animal Health Incorporated, valued at $1,626,367,200 using the latest closing price.
HOOVER R DAVID, the See Remarks of Elanco Animal Health Incorporated, purchase 5,000 shares at $28.62 during a trade that took place back on Aug 28, which means that HOOVER R DAVID is holding 45,000 shares at $143,100 based on the most recent closing price.
Stock Fundamentals for ELAN
Current profitability levels for the company are sitting at:
- +12.05 for the present operating margin
- +45.60 for the gross margin
The net margin for Elanco Animal Health Incorporated stands at +2.21. The total capital return value is set at 4.73, while invested capital returns managed to touch 0.87. Equity return is now at value -3.60, with -2.20 for asset returns.
Based on Elanco Animal Health Incorporated (ELAN), the company’s capital structure generated 44.00 points at debt to equity in total, while total debt to capital is 30.55. Total debt to assets is 27.16, with long-term debt to equity ratio resting at 43.13. Finally, the long-term debt to capital ratio is 29.95.
When we switch over and look at the enterprise to sales, we see a ratio of 4.23, with the company’s debt to enterprise value settled at 0.19. The receivables turnover for the company is 3.84 and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.90.